Currently out of the existing stock ratings of Roger Song, 114 are a BUY (89.06%), 13 are a HOLD (10.16%), 1 are a SELL (0.78%).

Roger Song

Work Performance Price Targets & Ratings Chart

Analyst Roger Song, currently employed at JEFFERIES, carries an average stock price target met ratio of 35.9% that have a potential upside of 29.8% achieved within 119 days.

Roger Song’s has documented 256 price targets and ratings displayed on 45 stocks. The coverage is on Healthcare, Basic Materials sectors.

Most recent stock forecast was given on INO, Inovio Pharmaceuticals at 13-Aug-2026.

Wall Street Analyst Roger Song

Analyst best performing recommendations are on REPL (REPLIMUNE GROUP).
The best stock recommendation documented was for REPL (REPLIMUNE GROUP) at 4/13/2026. The price target of $2 was fulfilled within 2 days with a profit of $0.3 (17.65%) receiving and performance score of 88.24.

Average potential price target upside

BCEL Atreca REPL Replimune Group AADI Aadi Bioscience CRVS Corvus Pharmaceuticals CTMX CytomX Therapeutics GLYC GlycoMimetics KNTE Kinnate Biopharma NKTR Nektar Therapeutics ACRS Aclaris Therapeutics ALT Altimmune NVAX Novavax IGMS IGM Biosciences FNCH Finch Therapeutics Group ICVX Icosavax INO Inovio Pharmaceuticals KURA Kura Oncology BIOA BioAge Labs GPCR Structure Therapeutics American Depositary Shares TRML Tourmaline Bio LVTX LAVA Therapeutics NV EQ Equillium KNSA Kiniksa Pharmaceuticals Ltd PCVX Vaxcyte PTGX Protagonist Therapeutics TGTX TG Therapeutics KRYS Krystal Biotech VKTX Viking Therapeutics WVE Wave Life Sciences Ltd AKBA Akebia Ther BMEA Biomea Fusion CVAC CureVac NV IRON Disc Medicine MT ArcelorMittal SA ADR PIRS Pieris Pharmaceuticals PRLD Prelude Therapeutics SANA Sana Biotechnology STRO Sutro Biopharma ALLO Allogene Therapeutics NRIX Nurix Therapeutics UTHR United Therapeutics VERV Verve Therapeutics ACRX AcelRx Pharmaceuticals ACRV Acrivon Therapeutics, Common Stock ORKA Oruka Therapeutics SABS SAB Biotherapeutics

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date of last PT

Price targets met ratio

Average potential upside

Average Days to Hit Target

Performance score

Hold

$1

$0.7 (233.33%)

$4

3 years 2 months 4 days ago
(14-Aug-2023)

0/6 (0%)

$0.49 (96.08%)

Hold

$1

$0.7 (233.33%)

$4

3 years 2 months 7 days ago
(11-Aug-2023)

0/6 (0%)

$0.44 (78.57%)

Buy

$25

3 years 2 months 7 days ago
(11-Aug-2023)

0/4 (0%)

$18.48 (1258.95%)

Buy

$20

3 years 6 months 17 days ago
(31-Mar-2023)

1/3 (33.33%)

$14.51 (264.30%)

220

Buy

$27

4 years 4 months 29 days ago
(19-May-2022)

0/1 (0%)

$18.23 (207.87%)

Show more analysts

Please expand the browser size to see the chart

Which stock is Roger Song most bullish on?

Potential upside of $114.22 has been obtained for NKTR (NEKTAR THERAPEUTICS)

Which stock is Roger Song most reserved on?

Potential downside of -$7.59 has been obtained for KNSA (KINIKSA PHARMACEUTICALS LTD)

What Year was the first public recommendation made by Roger Song?

On 2018
✖

To continue looking at which analysts cover the stock please register to the basic or advanced membership

What is AnaChart?